Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803]
Leuk Res. 2022 Apr:115:106811.
doi: 10.1016/j.leukres.2022.106811.
Epub 2022 Feb 24.
1 Hematology Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy; Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy. Electronic address: eleonora.debellis@asugi.sanita.fvg.it.
2 Hematology Section, Department of Medicine, Azienda Ospedale Università Padova, Italy.
3 Division of Hematology and SCT, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
4 Hematology Department, San Bortolo Hospital, Azienda ULSS8 "Berica" of Vicenza, Vicenza, Italy.
5 Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
6 Hematology Section, Dipartimento di Medicina Specialistica, Ca' Foncello Hospital, Treviso, Italy.
7 Ematologia e CTMO - Ospedale Regionale "S. Maurizio", Comprensorio Sanitario di Bolzano, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy.
8 Hematology Unit, Azienda Ulss3 Serenissima, Ospedale dell'Angelo, Venezia-Mestre, Italy.
9 Hematology Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
10 AULSS7 Pedemontana, U.O.C. Oncoematologia, Bassano del Grappa (VI), Italy.
12 Hematology Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Italy.